A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: Impact on quality-adjusted life expectancy and costs

Value in Health

Volumn 15, Issue 8, 2012, Pages 1014-1021

  Hornberger, John ^a,b   Lyman, Gary H ^c   Chien, Rebecca ^b,d   Meropol, Neal J ^e  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Cedar Associates LLC   (United States)

^c DUKE CANCER INSTITUTE   (United States)

^d Department of Medicine   (United States)

^e UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

cancer; cost effectiveness; cost utility; health economics; technological change

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINATE CALCIUM; FOLINIC ACID; OXALIPLATIN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER STAGING; COLON CANCER; COST CONTROL; DIARRHEA; FEBRILE NEUTROPENIA; FEMALE; HEALTH CARE COST; HUMAN; LIFE EXPECTANCY; LYMPH NODE; LYMPH VESSEL METASTASIS; MALE; MISMATCH REPAIR; NEUROPATHY; NEUTROPENIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; QUALITY ADJUSTED LIFE YEAR; RECURRENCE SCORE; SCORING SYSTEM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; COST-BENEFIT ANALYSIS; HUMANS; LIFE EXPECTANCY; MARKOV CHAINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; QUALITY-ADJUSTED LIFE YEARS; UNITED STATES;

EID: 84871253462     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2012.07.012     Document Type: Article

References (44)

1. A. Jemal, R. Siegel, and E. Ward Cancer statistics, 2009 CA Cancer J Clin 59 2009 225 249
2. National Cancer Institute: Division of Cancer Control & Population Sciences: Surveillance Research Program: Cancer Statistics Branch. Surveillance Epidemiology and End Results (SEER) Program. SEER*Stat Database. http://seer.cancer.gov/. [Accessed 2010].
3. A.B. Benson 3rd, D. Schrag, and M.R. Somerfield American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer J Clin Oncol 22 2004 3408 3419 (Pubitemid 41103700)
4. D. Schrag, S. Rifas-Shiman, and L. Saltz Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer J Clin Oncol 20 2002 3999 4005
5. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Colon cancer V.3.2010. www.nccn.org. [Accessed November 21, 2011].
6. Sargent DJ, Marsoni S., Thibodeau SN, et al. Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): A pooled molecular reanalysis of randomized chemotherapy trials. (Abstract no. 4008). American Society of Clinical Oncology Annual Meeting. Chicago, IL, 2008.
7. R. Gray, J. Barnwell, and C. McConkey Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study Lancet 370 2007 2020 2029
8. T. Andre, C. Boni, and M. Navarro Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial J Clin Oncol 27 2009 3109 3116
9. De Gramont A, Boni C, Navarro M, et al. Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years. (Abstract no. 4007). American Society of Clinical Oncology Annual Meeting. Chicago, IL, 2007.
10. C.C. Earle, M.R. Weiser, and A. Ter Veer Effect of lymph node retrieval rates on the utilization of adjuvant chemotherapy in stage II colon cancer J Surg Oncol 100 2009 525 528
11. A.T. Lu, S.R. Salpeter, and A.E. Reeve Gene expression profiles as predictors of poor outcomes in stage II colorectal cancer: A systematic review and meta-analysis Clin Colorectal Cancer 8 2009 207 214
12. R.G. Gray, P. Quirke, and K. Handley Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer J Clin Oncol 29 2011 4611 4619
13. Venook A, Niedzwiecki D, Lopatin M, et al. Validation of a 12-gene colon cancer recurrence score (RS) in patients (pts) with stage II colon cancer (CC) from CALGB 9581. (Abstract 3518). American Society of Clinical Oncology Annual Meeting. Chicago, IL, 2011.
14. O'Connell M, Lee M, Lopatin M, et al. Validation of the 12-gene colon cancer recurrence score (RS) in NSABP C07 as a predictor of recurrence in stage II and III colon cancer patients treated with 5FU/LV (FU) and 5FU/LV+oxaliplatin (FU+Ox). (Abstract 3512). American Society of Clinical Oncology Annual Meeting Chicago, IL, 2012.
15. M. Drummond, D. Brixner, and M. Gold Toward a consensus on the QALY Value Health 12 Suppl 1 2009 S31 S35
16. J.H. Best, L.P. Garrison, and W. Hollingworth Preference values associated with stage III colon cancer and adjuvant chemotherapy Qual Life Res 19 2010 391 400
17. Interactive Clinical Intelligence. OncoReport: Medical Oncology, 2nd Trimester 2009:Slide #232.
18. Centers of Medicare and Medicaid Services. Medicare Part B Drug Average Sales Price: 2010 ASP Drug Pricing File. Effective April 1, 2010. http://www.cms.gov/McrPartBDrugAvgSalesPrice/. [Accessed November 21, 2011].
19. S. Aballea, J.V. Chancellor, and M. Raikou Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US Cancer 109 2007 1082 1089 (Pubitemid 46435386)
20. E. Chu, K.L. Schulman, and S. Zelt Costs associated with complications are lower with capecitabine than with 5-fluorouracil in patients with colorectal cancer Cancer 115 2009 1412 1423
21. L.S. Elting, C. Lu, and C.P. Escalante Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia J Clin Oncol 26 2008 606 611 (Pubitemid 351264355)
22. S.A. Ferro, B.S. Myer, and D.A. Wolff Variation in the cost of medications for the treatment of colorectal cancer Am J Manag Care 14 2008 717 725
23. I. Lansdorp-Vogelaar, M. van Ballegooijen, and A.G. Zauber Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening J Natl Cancer Inst 101 2009 1412 1422
24. N. Lathia, N. Mittmann, and C. DeAngelis Evaluation of direct medical costs of hospitalization for febrile neutropenia Cancer 116 2010 742 748
25. QUASAR Collaborative Group Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial Lancet 355 2000 1588 1596
26. T. Andre, C. Boni, and L. Mounedji-Boudiaf Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer N Engl J Med 350 2004 2343 2351 (Pubitemid 38702845)
27. W. Scheithauer, J. McKendrick, and S. Begbie Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial Ann Oncol 14 2003 1735 1743 (Pubitemid 38029045)
28. C. Twelves, A. Wong, and M.P. Nowacki Capecitabine as adjuvant treatment for stage III colon cancer N Engl J Med 352 2005 2696 2704 (Pubitemid 41007824)
29. M.L. Brown, S.G. Nayfield, and L.M. Shibley Adjuvant therapy for stage III colon cancer: economics returns to research and cost-effectiveness of treatment J Natl Cancer Inst 86 1994 424 430 (Pubitemid 24081873)
30. S. Eggington, P. Tappenden, and A. Pandor Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer Br J Cancer 95 2006 1195 1201 (Pubitemid 44658483)
31. R.M. Ness, A.M. Holmes, and R. Klein Utility valuations for outcome states of colorectal cancer Am J Gastroenterol 94 1999 1650 1657 (Pubitemid 29260460)
32. Tufts Medical Center: Institute for Clinical Research and Health Policy Studies. The Cost-Effectiveness Analysis Registry. www.cearegistry.org. [Accessed November 21, 2011].
33. S.D. Ramsey, M.R. Andersen, and R. Etzioni Quality of life in survivors of colorectal carcinoma Cancer 88 2000 1294 1303 (Pubitemid 30155164)
34. M.C. Weinstein, B. O'Brien, and J. Hornberger Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices - Modeling Studies Value Health 6 2003 9 17 (Pubitemid 36228345)
35. M.S.J. Weinstein, M. Gold, M. Kamlet, and L. Russell Recommendations of the panel on cost-effectiveness in health and medicine JAMA 176 1999 1253 1258
36. A.H. Briggs, K. Claxton, and M.J. Sculpher Decision modelling for health economic evaluation ed.) 2006 Oxford University Press Oxford
37. T. Hastie, R. Tibshirani, and J. Friedman The Elements of Statistical Learning. ed.) 2001 Springer New York
38. M. Schonlau Boosted regression (boosting): An introductory tutorial and a Stata plugin The Stata Journal 5 2005 330 354 (Pubitemid 43708467)
39. C.D. Blanke Perforation and Stage-II Colon Cancer: Is it Always High Risk? Gastrointest Cancer Res 2 2008 103 104
40. P. Chun, and Z.A. Wainberg Adjuvant Chemotherapy for Stage II Colon Cancer: The Role of Molecular Markers in Choosing Therapy Gastrointest Cancer Res 3 2009 191 196
41. H.J. Lenz Prognostic/Predictive molecular markers in colorectal cancer Gastrointest Cancer Res 1 2007 S29 S32
42. Rosenberg R, Maak M, Simon I, et al. Independent validation of a prognostic genomic profile (ColoPrint) for stage II colon cancer (CC) patients. (Abstract 358). Gastrointestinal Cancers Symposium. San Francisco, CA, 2011.
43. E.S. O'Connor, D.Y. Greenblatt, and N.K. LoConte Adjuvant chemotherapy for stage II colon cancer with poor prognostic features J Clin Oncol 29 2011 3381 3388
44. N.J. Meropol Ongoing challenge of stage II colon cancer J Clin Oncol 29 2011 3346 3348